M. S. Tarasov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
M. S. Tarasov has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Anna S. Derbeneva
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
12 shared publications - Anzhella Zh. Fursova
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
12 shared publications - Yu. A. Karlash
Novosibirsk Regional Clinical Hospita; Novosibirsk State Medical University
11 shared publications - I. F. Nikulich
Novosibirsk Regional Clinical Hospita; Novosibirsk State Medical University
10 shared publications - Maria A. Vasilyeva
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
9 shared publications - E. I. Dmitrieva
Novosibirsk State Medical University
4 shared publications
Latest Publications
- 16 October 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (5)
Subretinal fibrosis in neovascular age-related macular degeneration: risk factors, mechanisms of development, and current options for prevention and treatment
The results of numerous randomized clinical trials and clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of the neovascular complex in neovascular age-related macular degeneration (nAMD). At the same time, a reduction in the risk of macular fibrosis has been demonstrated, with its incidence decreasing from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% during anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, timing of treatment initiation, treatment regimen and regularity, and type of drug. Fluctuations in retinal thickness and volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and hinder complete restoration of ellipsoid zone integrity. Extensive investigation of the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with production of TGF-β and CTGF, as well as cross-talk with classical fibrotic pathways. The synergistic action of Ang-2 and VEGF-A promotes subretinal scarring and underscores the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may sustain tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema, but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as evidenced by a significant reduction in SHRM volume — a key precursor of fibrotic changes.
- 16 October 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (5)
Subretinal fibrosis in neovascular age-related macular degeneration: risk factors, mechanisms of development, and current options for prevention and treatment
The results of numerous randomized clinical trials and clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of the neovascular complex in neovascular age-related macular degeneration (nAMD). At the same time, a reduction in the risk of macular fibrosis has been demonstrated, with its incidence decreasing from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% during anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, timing of treatment initiation, treatment regimen and regularity, and type of drug. Fluctuations in retinal thickness and volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and hinder complete restoration of ellipsoid zone integrity. Extensive investigation of the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with production of TGF-β and CTGF, as well as cross-talk with classical fibrotic pathways. The synergistic action of Ang-2 and VEGF-A promotes subretinal scarring and underscores the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may sustain tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema, but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as evidenced by a significant reduction in SHRM volume — a key precursor of fibrotic changes.
- Open Access
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 573-582
Hyperreflective Focuses as a Biomarker of Optical Coherence Tomography in Retinal Diseases: Pathogenesis, Visualization, and Clinical Significance
The presented literature review is devoted to an important OCT biomarker of retinal diseases; hyperreflective foci (GRF); which are considered as a promising indicator of inflammatory processes and vascular disorders of the retina. The purpose is to clarify modern ideas about the nature and classification of hyperreflective foci as an important diagnostic marker. This is necessary to improve the accuracy of diagnosis and monitoring of the most common retinal diseases; as well as to develop personalized treatment approaches; including using artificial intelligence technologies in ophthalmology. GRFs are defined as discrete point or rounded structures with increased optical density; ranging in size from 20 to 100 microns; localized within the retinal layers or in the subretinal space. GRF is not a specific morphological feature; but a universal phenotype reflecting a wide range of pathophysiological processes. The article describes in detail the morphology of foci; the pathogenetic mechanisms of their formation; the prognostic role and differences in age-related macular degeneration; diabetic retinopathy; diabetic macular edema. The correct differential interpretation of GRF requires an integrated approach; including an analysis of medical history and risk factors; a detailed assessment of their localization and morphological characteristics; as well as consideration of concomitant OCT signs and multimodal imaging data. The integration of these parameters makes it possible to accurately determine the nature of hyperreflective foci; choose the optimal patient management tactics; and reasonably predict the course of the disease.
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 573-582
Open AccessHyperreflective Focuses as a Biomarker of Optical Coherence Tomography in Retinal Diseases: Pathogenesis, Visualization, and Clinical Significance
The presented literature review is devoted to an important OCT biomarker of retinal diseases; hyperreflective foci (GRF); which are considered as a promising indicator of inflammatory processes and vascular disorders of the retina. The purpose is to clarify modern ideas about the nature and classification of hyperreflective foci as an important diagnostic marker. This is necessary to improve the accuracy of diagnosis and monitoring of the most common retinal diseases; as well as to develop personalized treatment approaches; including using artificial intelligence technologies in ophthalmology. GRFs are defined as discrete point or rounded structures with increased optical density; ranging in size from 20 to 100 microns; localized within the retinal layers or in the subretinal space. GRF is not a specific morphological feature; but a universal phenotype reflecting a wide range of pathophysiological processes. The article describes in detail the morphology of foci; the pathogenetic mechanisms of their formation; the prognostic role and differences in age-related macular degeneration; diabetic retinopathy; diabetic macular edema. The correct differential interpretation of GRF requires an integrated approach; including an analysis of medical history and risk factors; a detailed assessment of their localization and morphological characteristics; as well as consideration of concomitant OCT signs and multimodal imaging data. The integration of these parameters makes it possible to accurately determine the nature of hyperreflective foci; choose the optimal patient management tactics; and reasonably predict the course of the disease.
- 18 August 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (4) , 120-126
The effect of angiogenesis inhibitor therapy on the risk of fibrosis formation in neovascular age-related macular degeneration and potential strategies for its prevention
Numerous randomized clinical trials and real-world clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of neovascular complexes in neovascular age-related macular degeneration (nAMD), with a proven reduction in the risk of macular fibrosis, the incidence of which decreased from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% after introduction of anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, time of therapy initiation, treatment regimen, its regularity, and the type of drug. Variations in retinal thickness and the volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and prevent full restoration of the integrity of the ellipsoid zone. Extensive research into the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with the production of TGF-β and CTGF, and cross-talk with classical fibrotic pathways. The synergism between Ang-2 and VEGF-A stimulates subretinal scarring and highlights the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may support tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as confirmed by a significant reduction in the volume of SHRM — a key precursor to fibrotic changes.
- 18 August 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (4) , 120-126
The effect of angiogenesis inhibitor therapy on the risk of fibrosis formation in neovascular age-related macular degeneration and potential strategies for its prevention
Numerous randomized clinical trials and real-world clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of neovascular complexes in neovascular age-related macular degeneration (nAMD), with a proven reduction in the risk of macular fibrosis, the incidence of which decreased from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% after introduction of anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, time of therapy initiation, treatment regimen, its regularity, and the type of drug. Variations in retinal thickness and the volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and prevent full restoration of the integrity of the ellipsoid zone. Extensive research into the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with the production of TGF-β and CTGF, and cross-talk with classical fibrotic pathways. The synergism between Ang-2 and VEGF-A stimulates subretinal scarring and highlights the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may support tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as confirmed by a significant reduction in the volume of SHRM — a key precursor to fibrotic changes.
- Open Access
- 14 December 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (4) , 55-61
Evaluation of the efficacy of surgical treatment of cataracts in patients with neovascular age-related macular degeneration
Purpose. To study of the effectiveness of cataract surgery based on the results of a comprehensive evaluation, including the patient's opinion about the state of visual functions, when assessed using a questionnaire before and after surgery.Material and methods. 117 patients (117 eyes) diagnosed with nAMD and cataract (LOCS I — 56 patients, 47.9 %; LOCS II — 57 patients, 48.7 %, LOCS III — 4 patients, 3.4 %), mean age 76.2 ± 5.7 years were included in the study. All patients received angiogenesis inhibitor therapy (aflibercept 2 mg), in Treat&Extend regimen. Cataract surgery was performed if disease activity is controlled. A questionnaire including 10 questions was developed to interview patients, 9 of which were assessed before, 1 and 6 months after cataract surgery, and a 10th question on patient satisfaction with the results of surgery — 1 and 6 months after cataract surgery.Results. There was a significant improvement in functional (increase in BCVA by 0.31 units from the baseline) and anatomical parameters (significant decrease in CRT, height of neuro- and pigment epithelium detachment), as well as in patients' assessment of vision-related quality of life. The most compromised aspect before surgery was the ability to read text in newspapers, books, and magazines. After surgery there was a significant improvement of the indicators characterizing the patient's adaptation to navigation and outside activities. There were minimal changes in central vision loss and metamorphopsia as assessed by patients (on average, by 0.02 b. and 1.21 b.). 99 patients (84.0 %) reported satisfaction with the results of the surgery. The strongest correlations (r = 0.94 and 0.81, p < 0.05) characterized the relationship between patients' evaluation of the effect of surgery and the presence of central vision spotting/loss of central vision, double vision.Conclusion. The results of surgery significantly contribute to the patient's assessment of his/her daily activities requiring clearer vision, primarily in the middle and far distances. Cataract surgery does not worsen the course of nAMD and, on the contrary, cataract surgery and continuation of antiangiogenic therapy contribute to a significant improvement in BCVA and anatomical improvement.
- 14 December 2024
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 17 (4) , 55-61
Open AccessEvaluation of the efficacy of surgical treatment of cataracts in patients with neovascular age-related macular degeneration
Purpose. To study of the effectiveness of cataract surgery based on the results of a comprehensive evaluation, including the patient's opinion about the state of visual functions, when assessed using a questionnaire before and after surgery.Material and methods. 117 patients (117 eyes) diagnosed with nAMD and cataract (LOCS I — 56 patients, 47.9 %; LOCS II — 57 patients, 48.7 %, LOCS III — 4 patients, 3.4 %), mean age 76.2 ± 5.7 years were included in the study. All patients received angiogenesis inhibitor therapy (aflibercept 2 mg), in Treat&Extend regimen. Cataract surgery was performed if disease activity is controlled. A questionnaire including 10 questions was developed to interview patients, 9 of which were assessed before, 1 and 6 months after cataract surgery, and a 10th question on patient satisfaction with the results of surgery — 1 and 6 months after cataract surgery.Results. There was a significant improvement in functional (increase in BCVA by 0.31 units from the baseline) and anatomical parameters (significant decrease in CRT, height of neuro- and pigment epithelium detachment), as well as in patients' assessment of vision-related quality of life. The most compromised aspect before surgery was the ability to read text in newspapers, books, and magazines. After surgery there was a significant improvement of the indicators characterizing the patient's adaptation to navigation and outside activities. There were minimal changes in central vision loss and metamorphopsia as assessed by patients (on average, by 0.02 b. and 1.21 b.). 99 patients (84.0 %) reported satisfaction with the results of the surgery. The strongest correlations (r = 0.94 and 0.81, p < 0.05) characterized the relationship between patients' evaluation of the effect of surgery and the presence of central vision spotting/loss of central vision, double vision.Conclusion. The results of surgery significantly contribute to the patient's assessment of his/her daily activities requiring clearer vision, primarily in the middle and far distances. Cataract surgery does not worsen the course of nAMD and, on the contrary, cataract surgery and continuation of antiangiogenic therapy contribute to a significant improvement in BCVA and anatomical improvement.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 7-14
Analysis of the effectiveness of cataract surgery in neovascular age-related macular degeneration
Purpose. This study evaluated the impact of phacoemulsification cataract surgery (PE) on anatomical and functional parameters, as well as the regimen and frequency of anti-VEGF injections in patients with neovascular age-related macular degeneration (nAMD) over a long-term period (up to 3 years). Material and Methods. The study included 117 patients (117 eyes) diagnosed with nAMD and cataract, graded by LOCS: LOCS I (n=56; 47.9%), LOCS II (n=57; 48.7%), LOCS III (n=4; 3.4%); the average age of the patients was 76.2±5.7 years. All patients received anti-VEGF therapy (aflibercept 2 mg) following the treat-and-extend protocol. PE was performed only with disease activity under control. The observation period included 12 months before PE and 36 months after, with eight checkpoints for standard ophthalmological examination. Results. The average number of injections before PE was 6.85±1.78. In the first year after PE, the injection frequency increased to 7.85±0.83, then decreased to 7.04±1.50 in the second year and 3.85±1.22 in the third, with intervals between injections lengthening (to 13.35±1.84 weeks by the third year). All eyes (100%) demonstrated significant improvement in best-corrected visual acuity (BCVA), with an absolute increase of 0.28 from pre-PE baseline (from 0.22±0.17 to 0.50±0.18 by study end). There was a positive trend in reduction of central retinal thickness (by 138.5 μm or 36.5%) compared to baseline at the start of treatment, as well as reduction in neuroretinal and retinal pigment epithelial detachment over the observation period. Statistically significant correlations were found between BCVA, injection frequency, injection interval, and morphological biomarkers of nAMD activity over time. Conclusion. Initiation of antiangiogenic therapy in nAMD patients and the continuation of individualized monitoring and treatment after PE is associated with effective suppression of nAMD activity, improvement in functional and anatomical parameters, and a reduction in the number of intravitreal injections both in the short term and the long term.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 140 (6) , 7-14
Analysis of the effectiveness of cataract surgery in neovascular age-related macular degeneration
Purpose. This study evaluated the impact of phacoemulsification cataract surgery (PE) on anatomical and functional parameters, as well as the regimen and frequency of anti-VEGF injections in patients with neovascular age-related macular degeneration (nAMD) over a long-term period (up to 3 years). Material and Methods. The study included 117 patients (117 eyes) diagnosed with nAMD and cataract, graded by LOCS: LOCS I (n=56; 47.9%), LOCS II (n=57; 48.7%), LOCS III (n=4; 3.4%); the average age of the patients was 76.2±5.7 years. All patients received anti-VEGF therapy (aflibercept 2 mg) following the treat-and-extend protocol. PE was performed only with disease activity under control. The observation period included 12 months before PE and 36 months after, with eight checkpoints for standard ophthalmological examination. Results. The average number of injections before PE was 6.85±1.78. In the first year after PE, the injection frequency increased to 7.85±0.83, then decreased to 7.04±1.50 in the second year and 3.85±1.22 in the third, with intervals between injections lengthening (to 13.35±1.84 weeks by the third year). All eyes (100%) demonstrated significant improvement in best-corrected visual acuity (BCVA), with an absolute increase of 0.28 from pre-PE baseline (from 0.22±0.17 to 0.50±0.18 by study end). There was a positive trend in reduction of central retinal thickness (by 138.5 μm or 36.5%) compared to baseline at the start of treatment, as well as reduction in neuroretinal and retinal pigment epithelial detachment over the observation period. Statistically significant correlations were found between BCVA, injection frequency, injection interval, and morphological biomarkers of nAMD activity over time. Conclusion. Initiation of antiangiogenic therapy in nAMD patients and the continuation of individualized monitoring and treatment after PE is associated with effective suppression of nAMD activity, improvement in functional and anatomical parameters, and a reduction in the number of intravitreal injections both in the short term and the long term.
- 1 September 2023
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 13 (3) , 105-115
Current Data on the Age-Related Macular Degeneration Pathophysiology: Focus on Growth Factors and Neurotrophins
Age is a main risk factor for age-related macular degeneration (AMD), a complex multifactorial neurodegenerative retinal disease that is becoming the leading cause of vision loss in people over 55 years in developed countries. The risk of developing and rate of progression of AMD, as well as response to therapy, depend on the interaction of multiple genetic and environmental factors. In advanced stage, AMD is classified into dry atrophic (dry) or neovascular (wet) form. Intravitreal injection of anti-vascular endothelial growth factor agents is currently the first-line therapy for neovascular AMD. Unfortunately, therapy for dry AMD is still challenging, owing to an insufficient knowledge of the exact pathogenetic mechanisms. Considering the heterogeneity of AMD and the complexity of influencing age-dependent physiological processes, aging and immune disorders, the most realistic seems to be the further development of antiangiogenic therapy with an expansion of the range of targets, prolongation of their action and improvement of the delivery system. The neuroprotective potential of exogenous neurotrophins for retinal neurons has been proven; however, in order to develop effective drugs for the dry form of AMD based on them, it is necessary to resolve the issue of ways to effectively deliver them to the retina. In this review we discuss the current data on the AMD pathophysiology with focus on the role of vascular growth factors and neurotrophins.
- 1 September 2023
- Published by Pleiades Publishing Ltd in Advances in Gerontology
- Vol. 13 (3) , 105-115
Current Data on the Age-Related Macular Degeneration Pathophysiology: Focus on Growth Factors and Neurotrophins
Age is a main risk factor for age-related macular degeneration (AMD), a complex multifactorial neurodegenerative retinal disease that is becoming the leading cause of vision loss in people over 55 years in developed countries. The risk of developing and rate of progression of AMD, as well as response to therapy, depend on the interaction of multiple genetic and environmental factors. In advanced stage, AMD is classified into dry atrophic (dry) or neovascular (wet) form. Intravitreal injection of anti-vascular endothelial growth factor agents is currently the first-line therapy for neovascular AMD. Unfortunately, therapy for dry AMD is still challenging, owing to an insufficient knowledge of the exact pathogenetic mechanisms. Considering the heterogeneity of AMD and the complexity of influencing age-dependent physiological processes, aging and immune disorders, the most realistic seems to be the further development of antiangiogenic therapy with an expansion of the range of targets, prolongation of their action and improvement of the delivery system. The neuroprotective potential of exogenous neurotrophins for retinal neurons has been proven; however, in order to develop effective drugs for the dry form of AMD based on them, it is necessary to resolve the issue of ways to effectively deliver them to the retina. In this review we discuss the current data on the AMD pathophysiology with focus on the role of vascular growth factors and neurotrophins.
- 16 March 2023
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 139 (1) , 138-146
Diagnosis and clinical features of non-exudative macular neovascularization
Macular neovascularization (MNV) is the process of new abnormal blood vessels formation in the choroid and/or retina. The widespread adoption of optical coherence tomography angiography (OCTA) has significantly expanded the possibilities of not only detecting pathological blood flow before the development of exudation and deterioration of visual acuity, but also determining its characteristics. The purpose of this review is to substantiate the criteria for choosing terminology and diagnostic markers of MNV. The term “non-exudative MNV” refers to type 1 neovascularization without intraretinal or subretinal exudation detected on repeated OCT scans in the course of at least 6 months. This type of MNV may include previously untreated, non-exudative membranes with a low tendency to exudate, as well as previously treated membranes that have become inactive or dormant and no longer require anti-angiogenic therapy. The criterion for dividing the non-exudative form of MNV into inactive (with a low growth rate and vascular density (VD) at baseline) and subclinical (with a high growth rate and VD) is the time of its activation, generally recognized as 6 months. The diagnostic criteria is the visualized “double layer” sign on OCT scans (retinal pigment epithelium and Bruch’s membrane), as well as patterns of neovascular membranes of varying sizes, morphology and localization on OCTA scans. The cumulative risk of conversion from subclinical to exudative at two years of follow-up is 13.6 times higher than in eyes without detectable neovascularization, which highlights the importance of frequent monitoring in this healthy eye population for early detection of MNV signs.
- 16 March 2023
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 139 (1) , 138-146
Diagnosis and clinical features of non-exudative macular neovascularization
Macular neovascularization (MNV) is the process of new abnormal blood vessels formation in the choroid and/or retina. The widespread adoption of optical coherence tomography angiography (OCTA) has significantly expanded the possibilities of not only detecting pathological blood flow before the development of exudation and deterioration of visual acuity, but also determining its characteristics. The purpose of this review is to substantiate the criteria for choosing terminology and diagnostic markers of MNV. The term “non-exudative MNV” refers to type 1 neovascularization without intraretinal or subretinal exudation detected on repeated OCT scans in the course of at least 6 months. This type of MNV may include previously untreated, non-exudative membranes with a low tendency to exudate, as well as previously treated membranes that have become inactive or dormant and no longer require anti-angiogenic therapy. The criterion for dividing the non-exudative form of MNV into inactive (with a low growth rate and vascular density (VD) at baseline) and subclinical (with a high growth rate and VD) is the time of its activation, generally recognized as 6 months. The diagnostic criteria is the visualized “double layer” sign on OCT scans (retinal pigment epithelium and Bruch’s membrane), as well as patterns of neovascular membranes of varying sizes, morphology and localization on OCTA scans. The cumulative risk of conversion from subclinical to exudative at two years of follow-up is 13.6 times higher than in eyes without detectable neovascularization, which highlights the importance of frequent monitoring in this healthy eye population for early detection of MNV signs.
- Open Access
- 3 January 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 14 (4) , 95-102-102
The role of optical coherence tomography angiography biomarkers in assessing the outcome of long-term anti-VEGF therapy of diabetic macular edema
Цель исследования — оценка динамики биомаркеров активности диабетического макулярного отека (ДМО) по данным оптической когерентной томографии — ангиографии и их связи с ответом на анти-VEGF терапию в течение двухлетнего наблюдения. Материал и методы. Обследованы 59 пациентов (101 глаз) в возрасте 60,27 ± 9,50 года. Среднее количество интравитреальных инъекций афлиберцепта за период лечения составило 12,87 ± 3,50. Исходные значения площади фовеолярной аваскулярной зоны (ФАЗ) — 0,37 ± 0,22 мм2 и индекса ациркулярности — 0,56 ± 0,14 через 5 мес сохранились неизменными — 0,36 ± 0,24 мм2 и 0,56 ± 0,12, оставаясь на этом уровне через 12 и 24 мес. Большая площадь ФАЗ, отмеченная в группе с дезорганизацией внутренних слоев сетчатки (DRIL), — 0,39 ± 0,21 мм2 , коррелировала с низкой остротой зрения (r = 0,67, p = 0,003). Индекс ациркулярности оставался неизменным, достоверных отличий в группах пациентов с DRIL не выявлено. Исходная средняя плотность сосудов в макулярной области после 5 загрузочных инъекций увеличилась с 12,33 ± 3,86 до 12,75 ± 1,14 мм, через год составила 13,48 ± 1,15 мм, через 2 года — 13,25 ± 3,39 мм, средняя плотность перфузии сетчатки с 29,81 ± 10,85 % к 5-му месяцу увеличилась до 31,55 ± 2,34 %, через 12 мес — до 32,91 ± 3,45 %, к концу периода наблюдения — до 31,41 ± 9,79 %. В группе с DRIL исходные показатели плотности сосудов и среднего объема перфузии были значимо ниже: 11,17 ± 2,09 мм против 13,49 ± 1,14 мм и 28,40 ± 4,53 % против 31,20 ± 2,44 %. Заключение. DRIL — биомаркер, отражающий нарушение капиллярного кровотока в поверхностном капиллярном сплетении и коррелирующий с функциональными результатами антиангиогенной терапии, может быть использован в качестве предиктора ее эффективности. На фоне антиангиогенной терапии ДМО показатели микроциркуляции (ФАЗ и индекс ациркулярности) сохранялись стабильными, а плотность сосудов и объем перфузии имели тенденцию к увеличению, что свидетельствовало об отсутствии ишемического повреждения.
- 3 January 2022
- Published by Real Time, Ltd. in Russian Ophthalmological Journal
- Vol. 14 (4) , 95-102-102
Open AccessThe role of optical coherence tomography angiography biomarkers in assessing the outcome of long-term anti-VEGF therapy of diabetic macular edema
Цель исследования — оценка динамики биомаркеров активности диабетического макулярного отека (ДМО) по данным оптической когерентной томографии — ангиографии и их связи с ответом на анти-VEGF терапию в течение двухлетнего наблюдения. Материал и методы. Обследованы 59 пациентов (101 глаз) в возрасте 60,27 ± 9,50 года. Среднее количество интравитреальных инъекций афлиберцепта за период лечения составило 12,87 ± 3,50. Исходные значения площади фовеолярной аваскулярной зоны (ФАЗ) — 0,37 ± 0,22 мм2 и индекса ациркулярности — 0,56 ± 0,14 через 5 мес сохранились неизменными — 0,36 ± 0,24 мм2 и 0,56 ± 0,12, оставаясь на этом уровне через 12 и 24 мес. Большая площадь ФАЗ, отмеченная в группе с дезорганизацией внутренних слоев сетчатки (DRIL), — 0,39 ± 0,21 мм2 , коррелировала с низкой остротой зрения (r = 0,67, p = 0,003). Индекс ациркулярности оставался неизменным, достоверных отличий в группах пациентов с DRIL не выявлено. Исходная средняя плотность сосудов в макулярной области после 5 загрузочных инъекций увеличилась с 12,33 ± 3,86 до 12,75 ± 1,14 мм, через год составила 13,48 ± 1,15 мм, через 2 года — 13,25 ± 3,39 мм, средняя плотность перфузии сетчатки с 29,81 ± 10,85 % к 5-му месяцу увеличилась до 31,55 ± 2,34 %, через 12 мес — до 32,91 ± 3,45 %, к концу периода наблюдения — до 31,41 ± 9,79 %. В группе с DRIL исходные показатели плотности сосудов и среднего объема перфузии были значимо ниже: 11,17 ± 2,09 мм против 13,49 ± 1,14 мм и 28,40 ± 4,53 % против 31,20 ± 2,44 %. Заключение. DRIL — биомаркер, отражающий нарушение капиллярного кровотока в поверхностном капиллярном сплетении и коррелирующий с функциональными результатами антиангиогенной терапии, может быть использован в качестве предиктора ее эффективности. На фоне антиангиогенной терапии ДМО показатели микроциркуляции (ФАЗ и индекс ациркулярности) сохранялись стабильными, а плотность сосудов и объем перфузии имели тенденцию к увеличению, что свидетельствовало об отсутствии ишемического повреждения.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (5) , 57-65
Choroidal microvascular dropout as a biomarker of glaucoma progression in patients with diabetes mellitus
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить частоту, особенности развития микрососудистых нарушений хориоидеи (choroidal microvascular dropout, CMvD) как возможного маркера тяжести глаукомного процесса и оценить влияние сахарного диабета (СД) на прогрессирование этих изменений. МАТЕРИАЛ И МЕТОДЫ В исследование включены 258 пациентов (258 глаз), которые распределены на группы: 1-я — 58 пациентов (58 глаз) с первичной открытоугольной глаукомой (ПОУГ) I стадии и СД; 2-я — 50 пациентов (50 глаз) с ПОУГ I стадии; 3-я — 50 пациентов (50 глаз) с ПОУГ III стадии и СД; 4-я — 50 пациентов (50 глаз) с ПОУГ III стадии; 5-я — 50 пациентов (50 глаз) с СД. Период наблюдения 24 мес. Оценивали частоту и динамику развития микрососудистых нарушений хориоидеи, их связь со структурными и функциональными показателями диска зрительного нерва (ДЗН) в процессе наблюдения у пациентов с ПОУГ на фоне СД. РЕЗУЛЬТАТЫ CMvD выявлены при изолированной ПОУГ I стадии в 17 (34%) глазах, у пациентов с СД — в 27 (54%), при сочетанном течении ПОУГ I стадии и СД — в 46 (79,31%), у пациентов с III стадией глаукомы — в 100% случаев. У пациентов с III стадией глаукомы показатели площади CMvD превысили значения в других группах и практически не отличались от таковых при наличии СД (0,59±0,13 мм2; p=0,005) и без него (0,57±0,14 мм2; p=0,005). В 1-й год наблюдения увеличение площади микрососудистых нарушений у пациентов с ПОУГ I стадии составило 5,88%, у коморбидных пациентов — 3,84%, но к концу периода наблюдения она увеличилась на 19,23%, а в группе пациентов с высокой скоростью прогрессирования — на 31,25%. Выявлены сильные значимые корреляции CMvD с MD (r=0,89), умеренные — со структурными показателями ДЗН (r=0,59), с гемодинамическими показателями (r=0,54 и r=0,52). ЗАКЛЮЧЕНИЕ Развитие CMvD является как результатом глаукомного повреждения зрительного нерва, так и следствием нарушения его гемодинамики на уровне глубокого капиллярного сплетения. Результаты исследования продемонстрировали неблагоприятное влияние СД на течение глаукомы, определяющего инициацию микроваскулярных нарушений, усугубляющих тяжесть глаукомного процесса и скорость прогрессирования.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (5) , 57-65
Choroidal microvascular dropout as a biomarker of glaucoma progression in patients with diabetes mellitus
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить частоту, особенности развития микрососудистых нарушений хориоидеи (choroidal microvascular dropout, CMvD) как возможного маркера тяжести глаукомного процесса и оценить влияние сахарного диабета (СД) на прогрессирование этих изменений. МАТЕРИАЛ И МЕТОДЫ В исследование включены 258 пациентов (258 глаз), которые распределены на группы: 1-я — 58 пациентов (58 глаз) с первичной открытоугольной глаукомой (ПОУГ) I стадии и СД; 2-я — 50 пациентов (50 глаз) с ПОУГ I стадии; 3-я — 50 пациентов (50 глаз) с ПОУГ III стадии и СД; 4-я — 50 пациентов (50 глаз) с ПОУГ III стадии; 5-я — 50 пациентов (50 глаз) с СД. Период наблюдения 24 мес. Оценивали частоту и динамику развития микрососудистых нарушений хориоидеи, их связь со структурными и функциональными показателями диска зрительного нерва (ДЗН) в процессе наблюдения у пациентов с ПОУГ на фоне СД. РЕЗУЛЬТАТЫ CMvD выявлены при изолированной ПОУГ I стадии в 17 (34%) глазах, у пациентов с СД — в 27 (54%), при сочетанном течении ПОУГ I стадии и СД — в 46 (79,31%), у пациентов с III стадией глаукомы — в 100% случаев. У пациентов с III стадией глаукомы показатели площади CMvD превысили значения в других группах и практически не отличались от таковых при наличии СД (0,59±0,13 мм2; p=0,005) и без него (0,57±0,14 мм2; p=0,005). В 1-й год наблюдения увеличение площади микрососудистых нарушений у пациентов с ПОУГ I стадии составило 5,88%, у коморбидных пациентов — 3,84%, но к концу периода наблюдения она увеличилась на 19,23%, а в группе пациентов с высокой скоростью прогрессирования — на 31,25%. Выявлены сильные значимые корреляции CMvD с MD (r=0,89), умеренные — со структурными показателями ДЗН (r=0,59), с гемодинамическими показателями (r=0,54 и r=0,52). ЗАКЛЮЧЕНИЕ Развитие CMvD является как результатом глаукомного повреждения зрительного нерва, так и следствием нарушения его гемодинамики на уровне глубокого капиллярного сплетения. Результаты исследования продемонстрировали неблагоприятное влияние СД на течение глаукомы, определяющего инициацию микроваскулярных нарушений, усугубляющих тяжесть глаукомного процесса и скорость прогрессирования.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (2) , 120-130
New findings on pathogenetic mechanisms in the development of age-related macular degeneration
Возрастная макулярная дегенерация (ВМД) — сложное многофакторное заболевание, возникающее в результате дисфункции и дегенерации ретинального пигментного эпителия (РПЭ), хориокапилляров и гибели фоторецепторов. При этом точный механизм патогенеза остается неизвестным. Старение является наиболее важным и наиболее твердо установленным фактором риска ВМД. Особую роль играет секреторный фенотип старения, распространяющийся от клетки к клетке и опосредованный секрецией и высвобождением факторов роста, цитокинов, хемокинов, протеаз и других молекул, способствующих развитию и прогрессированию заболевания. Также большое значение имеет окислительный стресс, возникающий вследствие нарушения рециркуляции витамина A в зрительном цикле и накопления липофусцина. Последний опосредует образование окислителей с участием железа, оказывающих токсическое действие на митохондрии. Кроме того, развитие воспаления в сетчатке обусловлено длительным воздействием окислительного стресса при постоянных световых воздействиях. Накопление продуктов обмена, а также клеточных дефектов с возрастом может вызывать воспалительную реакцию, которая усиливает уже имеющиеся повреждения. Воспалительные процессы, включая врожденный иммунный ответ, активацию микроглии и паравоспаление, локально происходящие в сосудистой оболочке, РПЭ и нейроретине, чрезвычайно важны для развития возрастных изменений, их прогрессирования до продвинутых стадий ВМД. Особую роль в развитии хориоидальной неоваскуляризации (ХНВ) играют различные факторы роста. Традиционно основным фактором неоангиогенеза и вследствие этого основной терапевтической мишенью считался VEGF-A, однако в последние годы определена роль и ведется активное изучение и других факторов — VEGF-B, -C, -D, PGF, Gal-1, ангиопоэтинов. В статье рассмотрены основные механизмы, влияющие на развитие хориоидальной неоваскуляризации, включая старение сетчатки, нарушение метаболической активности, дисфункцию митохондрий, воспалительные реакции и генетические вариации, а также описана роль различных факторов роста.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 138 (2) , 120-130
New findings on pathogenetic mechanisms in the development of age-related macular degeneration
Возрастная макулярная дегенерация (ВМД) — сложное многофакторное заболевание, возникающее в результате дисфункции и дегенерации ретинального пигментного эпителия (РПЭ), хориокапилляров и гибели фоторецепторов. При этом точный механизм патогенеза остается неизвестным. Старение является наиболее важным и наиболее твердо установленным фактором риска ВМД. Особую роль играет секреторный фенотип старения, распространяющийся от клетки к клетке и опосредованный секрецией и высвобождением факторов роста, цитокинов, хемокинов, протеаз и других молекул, способствующих развитию и прогрессированию заболевания. Также большое значение имеет окислительный стресс, возникающий вследствие нарушения рециркуляции витамина A в зрительном цикле и накопления липофусцина. Последний опосредует образование окислителей с участием железа, оказывающих токсическое действие на митохондрии. Кроме того, развитие воспаления в сетчатке обусловлено длительным воздействием окислительного стресса при постоянных световых воздействиях. Накопление продуктов обмена, а также клеточных дефектов с возрастом может вызывать воспалительную реакцию, которая усиливает уже имеющиеся повреждения. Воспалительные процессы, включая врожденный иммунный ответ, активацию микроглии и паравоспаление, локально происходящие в сосудистой оболочке, РПЭ и нейроретине, чрезвычайно важны для развития возрастных изменений, их прогрессирования до продвинутых стадий ВМД. Особую роль в развитии хориоидальной неоваскуляризации (ХНВ) играют различные факторы роста. Традиционно основным фактором неоангиогенеза и вследствие этого основной терапевтической мишенью считался VEGF-A, однако в последние годы определена роль и ведется активное изучение и других факторов — VEGF-B, -C, -D, PGF, Gal-1, ангиопоэтинов. В статье рассмотрены основные механизмы, влияющие на развитие хориоидальной неоваскуляризации, включая старение сетчатки, нарушение метаболической активности, дисфункцию митохондрий, воспалительные реакции и генетические вариации, а также описана роль различных факторов роста.